# A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

> **NCT00973024** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 389 (actual)

## Conditions studied

- Low Back Pain
- Low Back Pain, Recurrent

## Interventions

- **DRUG:** JNJ-42160443 3 mg
- **DRUG:** JNJ-42160443 1 mg
- **DRUG:** JNJ-42160443 6 mg/3mg
- **DRUG:** JNJ-42160443 10 mg
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT00973024
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 389 (ACTUAL)
- **Why stopped:** Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973024, "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00973024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*